A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
Comparing Docetaxel Plus Fulvestrant With Docetaxel in Patients With Metastatic Breast Cancer
Metastatic Breast Cancer
DRUG: Docetaxel|DRUG: Fulvestrant
Progression Free Survival, 6 weeks
Overall Response Rate, 6 Weeks|Overall Survival, 6 Weeks
Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor Positive and HER2-negative Metastatic Breast Cancer